Insiders who reported open-market trades in the last 12 months at the companies Kathryn E. Falberg files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jeffrey Terry Green - $148.10M in TTD purchases and sales in the last 12 months
Juan C. Jaen - $8.07M in RCUS purchases and sales in the last 12 months
Gary Hattersley - $3.88M in NUVB purchases and sales in the last 12 months
Dongfang Liu - $1.87M in NUVB purchases and sales in the last 12 months
Kerry Wentworth - $1.47M in NUVB purchases and sales in the last 12 months
David C. Hanley - $1.43M in NUVB purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Kathryn E. Falberg is a corporate insider, tracked as Director of Arcus Biosciences, Inc. (RCUS). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Kathryn E. Falberg last file a Form 4?
The most recent primary Form 4 on record is dated 12 June 2026, one of 8 filings going back to 2025.
Has Kathryn E. Falberg been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($4.66M) across all tracked filings.
Kathryn E. Falberg is Director of Arcus Biosciences, Inc. (RCUS). 8 SEC Form 4 filings on record going back to 2025, most recently on 12 June 2026. Most recent open-market trade: sold $1.52M of TTD on 9 March 2026. Lifetime open-market sales: $4.66M.
Recent transactions
13
The latest 13 SEC Form 4 transactions reported by Kathryn E. Falberg.
InsiderAlpha's records for Kathryn E. Falberg go back to 2025: 8 primary Form 4 filings, an average of 4.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
